Global Secondary Progressive Multiple Sclerosis Drug Market Research Report 2021

Global Secondary Progressive Multiple Sclerosis Drug Market Research Report 2021

Table of Contents
1 Secondary Progressive Multiple Sclerosis Drug Market Overview
1.1 Product Overview and Scope of Secondary Progressive Multiple Sclerosis Drug
1.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Inebilizumab
1.2.3 GLX-1112
1.2.4 DC-TAB
1.2.5 Etomoxir
1.2.6 IB-MS
1.2.7 Others
1.3 Secondary Progressive Multiple Sclerosis Drug Segment by Application
1.3.1 Secondary Progressive Multiple Sclerosis Drug Sales Comparison by Application: (2021-2027)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Secondary Progressive Multiple Sclerosis Drug Market Size Estimates and Forecasts
1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue 2016-2027
1.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales 2016-2027
1.4.3 Secondary Progressive Multiple Sclerosis Drug Market Size by Region: 2016 Versus 2021 Versus 2027
2 Secondary Progressive Multiple Sclerosis Drug Market Competition by Manufacturers
2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers (2016-2021)
2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Secondary Progressive Multiple Sclerosis Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Secondary Progressive Multiple Sclerosis Drug Manufacturing Sites, Area Served, Product Type
2.5 Secondary Progressive Multiple Sclerosis Drug Market Competitive Situation and Trends
2.5.1 Secondary Progressive Multiple Sclerosis Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue
2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario by Region
3.1 Global Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Country
3.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country
3.3.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Country
3.4.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country
3.4.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region
3.5.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Country
3.6.1 Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country
3.6.2 Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country
3.7.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Analysis by Type
4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
4.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2016-2021)
4.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2021)
5 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Analysis by Application
5.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2016-2021)
5.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2016-2021)
6 Key Companies Profiled
6.1 AB Science SA
6.1.1 AB Science SA Corporation Information
6.1.2 AB Science SA Description and Business Overview
6.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.1.4 AB Science SA Product Portfolio
6.1.5 AB Science SA Recent Developments/Updates
6.2 Actelion Ltd
6.2.1 Actelion Ltd Corporation Information
6.2.2 Actelion Ltd Description and Business Overview
6.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Actelion Ltd Product Portfolio
6.2.5 Actelion Ltd Recent Developments/Updates
6.3 Biogen, Inc.
6.3.1 Biogen, Inc. Corporation Information
6.3.2 Biogen, Inc. Description and Business Overview
6.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Biogen, Inc. Product Portfolio
6.3.5 Biogen, Inc. Recent Developments/Updates
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 F. Hoffmann-La Roche Ltd. Product Portfolio
6.4.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.5 Genzyme Corporation
6.5.1 Genzyme Corporation Corporation Information
6.5.2 Genzyme Corporation Description and Business Overview
6.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Genzyme Corporation Product Portfolio
6.5.5 Genzyme Corporation Recent Developments/Updates
6.6 Glialogix, Inc.
6.6.1 Glialogix, Inc. Corporation Information
6.6.2 Glialogix, Inc. Description and Business Overview
6.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Glialogix, Inc. Product Portfolio
6.6.5 Glialogix, Inc. Recent Developments/Updates
6.7 Immune Response BioPharma, Inc.
6.6.1 Immune Response BioPharma, Inc. Corporation Information
6.6.2 Immune Response BioPharma, Inc. Description and Business Overview
6.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Immune Response BioPharma, Inc. Product Portfolio
6.7.5 Immune Response BioPharma, Inc. Recent Developments/Updates
6.8 Innate Immunotherapeutics Ltd
6.8.1 Innate Immunotherapeutics Ltd Corporation Information
6.8.2 Innate Immunotherapeutics Ltd Description and Business Overview
6.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Innate Immunotherapeutics Ltd Product Portfolio
6.8.5 Innate Immunotherapeutics Ltd Recent Developments/Updates
6.9 Kyorin Pharmaceutical Co., Ltd.
6.9.1 Kyorin Pharmaceutical Co., Ltd. Corporation Information
6.9.2 Kyorin Pharmaceutical Co., Ltd. Description and Business Overview
6.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Kyorin Pharmaceutical Co., Ltd. Product Portfolio
6.9.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments/Updates
6.10 Mallinckrodt Plc
6.10.1 Mallinckrodt Plc Corporation Information
6.10.2 Mallinckrodt Plc Description and Business Overview
6.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Mallinckrodt Plc Product Portfolio
6.10.5 Mallinckrodt Plc Recent Developments/Updates
6.11 MedDay SA
6.11.1 MedDay SA Corporation Information
6.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.11.4 MedDay SA Product Portfolio
6.11.5 MedDay SA Recent Developments/Updates
6.12 MedImmune, LLC
6.12.1 MedImmune, LLC Corporation Information
6.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.12.4 MedImmune, LLC Product Portfolio
6.12.5 MedImmune, LLC Recent Developments/Updates
6.13 Merck KGaA
6.13.1 Merck KGaA Corporation Information
6.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Merck KGaA Product Portfolio
6.13.5 Merck KGaA Recent Developments/Updates
6.14 Meta-IQ ApS
6.14.1 Meta-IQ ApS Corporation Information
6.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Meta-IQ ApS Product Portfolio
6.14.5 Meta-IQ ApS Recent Developments/Updates
6.15 Novartis AG
6.15.1 Novartis AG Corporation Information
6.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Novartis AG Product Portfolio
6.15.5 Novartis AG Recent Developments/Updates
6.16 Opexa Therapeutics, Inc.
6.16.1 Opexa Therapeutics, Inc. Corporation Information
6.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Opexa Therapeutics, Inc. Product Portfolio
6.16.5 Opexa Therapeutics, Inc. Recent Developments/Updates
6.17 Xenetic Biosciences (UK) Limited
6.17.1 Xenetic Biosciences (UK) Limited Corporation Information
6.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Description and Business Overview
6.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Xenetic Biosciences (UK) Limited Product Portfolio
6.17.5 Xenetic Biosciences (UK) Limited Recent Developments/Updates
7 Secondary Progressive Multiple Sclerosis Drug Manufacturing Cost Analysis
7.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
7.4 Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Secondary Progressive Multiple Sclerosis Drug Distributors List
8.3 Secondary Progressive Multiple Sclerosis Drug Customers
9 Secondary Progressive Multiple Sclerosis Drug Market Dynamics
9.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
9.2 Secondary Progressive Multiple Sclerosis Drug Growth Drivers
9.3 Secondary Progressive Multiple Sclerosis Drug Market Challenges
9.4 Secondary Progressive Multiple Sclerosis Drug Market Restraints
10 Global Market Forecast
10.1 Secondary Progressive Multiple Sclerosis Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Secondary Progressive Multiple Sclerosis Drug by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Secondary Progressive Multiple Sclerosis Drug by Type (2022-2027)
10.2 Secondary Progressive Multiple Sclerosis Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Secondary Progressive Multiple Sclerosis Drug by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Secondary Progressive Multiple Sclerosis Drug by Application (2022-2027)
10.3 Secondary Progressive Multiple Sclerosis Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Secondary Progressive Multiple Sclerosis Drug by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Secondary Progressive Multiple Sclerosis Drug by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) Comparison by Application (2021-2027)
Table 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Covered in This Study
Table 5. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) of Key Manufacturers (2016-2021)
Table 6. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Manufacturers (2016-2021)
Table 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Secondary Progressive Multiple Sclerosis Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2016-2021) & (K Pcs)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2021)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021) & (K Pcs)
Table 19. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2021)
Table 20. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2021)
Table 22. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021) & (K Pcs)
Table 23. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2021)
Table 24. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2016-2021) & (K Pcs)
Table 27. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2016-2021)
Table 30. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021) & (K Pcs)
Table 31. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2021)
Table 32. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021) & (K Pcs)
Table 35. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2021)
Table 38. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2016-2021)
Table 39. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2021)
Table 40. Global Secondary Progressive Multiple Sclerosis Drug Revenue (Million US$) by Type (2016-2021)
Table 41. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2016-2021)
Table 42. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Type (2016-2021)
Table 43. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2016-2021)
Table 44. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2021)
Table 45. Global Secondary Progressive Multiple Sclerosis Drug Revenue (Million US$) by Application (2016-2021)
Table 46. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Application (2016-2021)
Table 47. Global Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Application (2016-2021)
Table 48. AB Science SA Corporation Information
Table 49. AB Science SA Description and Business Overview
Table 50. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 51. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product
Table 52. AB Science SA Recent Developments/Updates
Table 53. Actelion Ltd Corporation Information
Table 54. Actelion Ltd Description and Business Overview
Table 55. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 56. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 57. Actelion Ltd Recent Developments/Updates
Table 58. Biogen, Inc. Corporation Information
Table 59. Biogen, Inc. Description and Business Overview
Table 60. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 61. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 62. Biogen, Inc. Recent Developments/Updates
Table 63. F. Hoffmann-La Roche Ltd. Corporation Information
Table 64. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 65. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 66. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 67. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 68. Genzyme Corporation Corporation Information
Table 69. Genzyme Corporation Description and Business Overview
Table 70. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 71. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product
Table 72. Genzyme Corporation Recent Developments/Updates
Table 73. Glialogix, Inc. Corporation Information
Table 74. Glialogix, Inc. Description and Business Overview
Table 75. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 76. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 77. Glialogix, Inc. Recent Developments/Updates
Table 78. Immune Response BioPharma, Inc. Corporation Information
Table 79. Immune Response BioPharma, Inc. Description and Business Overview
Table 80. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 81. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 82. Immune Response BioPharma, Inc. Recent Developments/Updates
Table 83. Innate Immunotherapeutics Ltd Corporation Information
Table 84. Innate Immunotherapeutics Ltd Description and Business Overview
Table 85. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 86. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 87. Innate Immunotherapeutics Ltd Recent Developments/Updates
Table 88. Kyorin Pharmaceutical Co., Ltd. Corporation Information
Table 89. Kyorin Pharmaceutical Co., Ltd. Description and Business Overview
Table 90. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 91. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 92. Kyorin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 93. Mallinckrodt Plc Corporation Information
Table 94. Mallinckrodt Plc Description and Business Overview
Table 95. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 96. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product
Table 97. Mallinckrodt Plc Recent Developments/Updates
Table 98. MedDay SA Corporation Information
Table 99. MedDay SA Description and Business Overview
Table 100. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 101. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product
Table 102. MedDay SA Recent Developments/Updates
Table 103. MedImmune, LLC Corporation Information
Table 104. MedImmune, LLC Description and Business Overview
Table 105. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 106. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product
Table 107. MedImmune, LLC Recent Developments/Updates
Table 108. Merck KGaA Corporation Information
Table 109. Merck KGaA Description and Business Overview
Table 110. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 111. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product
Table 112. Merck KGaA Recent Developments/Updates
Table 113. Meta-IQ ApS Corporation Information
Table 114. Meta-IQ ApS Description and Business Overview
Table 115. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 116. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product
Table 117. Meta-IQ ApS Recent Developments/Updates
Table 118. Novartis AG Corporation Information
Table 119. Novartis AG Description and Business Overview
Table 120. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 121. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product
Table 122. Novartis AG Recent Developments/Updates
Table 123. Opexa Therapeutics, Inc. Corporation Information
Table 124. Opexa Therapeutics, Inc. Description and Business Overview
Table 125. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 126. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 127. Opexa Therapeutics, Inc. Recent Developments/Updates
Table 128. Xenetic Biosciences (UK) Limited Corporation Information
Table 129. Xenetic Biosciences (UK) Limited Description and Business Overview
Table 130. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 131. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product
Table 132. Xenetic Biosciences (UK) Limited Recent Developments/Updates
Table 133. Production Base and Market Concentration Rate of Raw Material
Table 134. Key Suppliers of Raw Materials
Table 135. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 136. Secondary Progressive Multiple Sclerosis Drug Customers List
Table 137. Secondary Progressive Multiple Sclerosis Drug Market Trends
Table 138. Secondary Progressive Multiple Sclerosis Drug Growth Drivers
Table 139. Secondary Progressive Multiple Sclerosis Drug Market Restraints
Table 140. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2022-2027) & (K Pcs)
Table 141. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Type (2022-2027)
Table 142. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 143. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Type (2022-2027)
Table 144. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2022-2027) & (K Pcs)
Table 145. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Application (2022-2027)
Table 146. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 147. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Application (2022-2027)
Table 148. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2022-2027) & (K Pcs)
Table 149. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Region (2022-2027)
Table 150. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 151. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Region (2022-2027)
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Secondary Progressive Multiple Sclerosis Drug
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2020 & 2027
Figure 3. Inebilizumab Product Picture
Figure 4. GLX-1112 Product Picture
Figure 5. DC-TAB Product Picture
Figure 6. Etomoxir Product Picture
Figure 7. IB-MS Product Picture
Figure 8. Others Product Picture
Figure 9. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2020 & 2027
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Secondary Progressive Multiple Sclerosis Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Secondary Progressive Multiple Sclerosis Drug Market Size 2016-2027 (US$ Million)
Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales 2016-2027 (K Pcs)
Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 17. Secondary Progressive Multiple Sclerosis Drug Sales Share by Manufacturers in 2020
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers in 2020
Figure 19. The Global 5 and 10 Largest Secondary Progressive Multiple Sclerosis Drug Players: Market Share by Revenue in 2020
Figure 20. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 21. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2021)
Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2020
Figure 23. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2016-2021)
Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region in 2020
Figure 25. U.S. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. U.K. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Indonesia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Thailand Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Malaysia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Philippines Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Vietnam Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2016-2021) (US$

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs